CD274 and non-small cell lung carcinoma: CodeBreaK 100 is a multicentre, single-arm, open-label clinical trial (ClinicalTrials.gov Identifier: NCT03600883) evaluating sotorasib alone and in combination with anti-PD-1/PD-L1, including patients with locally advanced or metastatic NSCLC with KRAS G12C mutations.